Market Overview

Poxel Appoints Takashi Kaneko, MD, PhD, as Senior Vice President Medical and President of Poxel Japan K.K.

Share:
  • Poxel has also established a Japanese subsidiary in Tokyo
  • Both events are strategic commitments to the Japanese and Asian markets

POXEL
SA
(Euronext – POXEL - FR0012432516), a biopharmaceutical company
focused on the development of innovative treatments for metabolic
disorders, including type 2 diabetes and non-alcoholic steatohepatitis
(NASH), today announced that Takashi Kaneko, MD, PhD, has joined
Poxel as Senior Vice President Medical and President of
Poxel Japan K.K., effective September 1, 2018, to lead the Company's
drug development and medical affairs activities as well as the team in
Japan. In addition, the Company has established a wholly-owned Japanese
subsidiary in Tokyo.

"Japan has been a strategic focus for Poxel and we have made significant
progress in the development of Imeglimin for the treatment of type 2
diabetes for this market. This includes a robust Phase 2b program, which
resulted in the strategic partnership with Sumitomo Dainippon Pharma for
Japan, China and eleven other Asian countries. We are also advancing the
Imeglimin Phase 3 TIMES program in Japan, with our partner Sumitomo, for
which we expect the first data results in the first half of 2019," said
Thomas Kuhn, CEO of Poxel. "The addition of Dr. Kaneko to our team with
his medical affairs and clinical development expertise and knowledge of
the Japanese market is of great importance to Poxel today and moving
forward as we continue to expand our efforts in Japan through our newly
established subsidiary in Tokyo."

Dr. Takashi Kaneko commented: "I am very excited to be working with the
Poxel team and supporting the completion of the Imeglimin Phase 3 TIMES
program. I am looking forward to working closely with our partner
Sumitomo Dainippon Pharma on the market access and medical plan for
patients and health care providers and making Imeglimin, a
first-in-class drug candidate, available to the Japanese and Asian
markets. In addition, I am looking forward to contributing to other
programs and new opportunities for Poxel in Japan."

Dr. Kaneko brings to Poxel over 33 years of experience including
pharmaceutical industry experience with a focus on medical affairs and
clinical development ranging from product evaluation, development and
post-commercial launch, and clinical practice and medical research
experience. Dr. Kaneko joins Poxel from Janssen Pharmaceutical K.K.,
where he was Head of Medical Affairs. Prior to Janssen Pharmaceutical
K.K., he was the Department Head of the Medical Excellence Department in
the Medical Division at Novartis K.K. Dr. Kaneko also held several
senior-level positions at Santen, which included the areas of
Compliance, Global Clinical Development and Medical Affairs, Head of
Global Research and Development as well as other research and
development-related positions. In addition, Dr. Kaneko was a Vice
President, Medical Director at Sanofi-Aventis K.K., and served in
clinical development roles at Bristol-Myers K.K., BMS, Japan. Dr. Kaneko
holds an MD and PhD degree from the University of Tokyo, Tokyo, Japan.

About Imeglimin

Imeglimin is the first clinical candidate in a new chemical class of
oral agents called Glimins by the World Health Organization. Imeglimin
has a unique mechanism of action ("MOA") that targets mitochondrial
bioenergetics. Imeglimin acts on all three key organs which play an
important role in the treatment of type 2 diabetes: the liver, muscles
and the pancreas, and it has demonstrated glucose lowering benefits by
increasing insulin secretion in response to glucose, improving insulin
sensitivity and suppressing gluconeogenesis. This MOA has the potential
to prevent endothelial and diastolic dysfunction, which can provide
protective effects on micro- and macro-vascular defects induced by
diabetes. It also has the potential for protective effect on beta-cell
survival and function. This unique MOA offers the potential opportunity
for Imeglimin to be a candidate for the treatment of type 2 diabetes in
almost all stages of the current anti-diabetic treatment paradigm,
including monotherapy or as an add-on to other glucose lowering
therapies.

About Poxel

Poxel uses its development expertise in metabolism to advance a pipeline
of drug candidates focused on the treatment of metabolic disorders,
including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We
have successfully completed the Phase 2 clinical program for our
first-in-class lead product, Imeglimin, which targets mitochondrial
dysfunction, in the U.S., Europe and Japan. Together, with our partner
Sumitomo Dainippon Pharma, we are conducting the Phase 3 Trials of
IMeglimin for Efficacy and Safety (TIMES)
program for the treatment of type 2 diabetes in Japan. Our
partner Roivant Sciences is responsible for Imeglimin's
development and commercialization in countries outside of Poxel's
partnership with Sumitomo Dainippon Pharma, including the U.S. and
Europe. PXL770, a first in class direct adenosine
monophosphate-activated protein kinase (AMPK) activator, is advancing
into a Phase 2a proof-of-concept program for the treatment of NASH.
PXL770 could also have the potential to treat additional metabolic
diseases. DRX-065 (deuterium-stabilized R-pioglitazone), a mitochondrial
pyruvate carrier (MPC), is in Phase 1 and being developed for the
treatment of NASH. Poxel also has additional earlier-stage programs,
including deuterated drug candidates for metabolic, specialty and rare
diseases. We intend to generate further growth through strategic
partnerships and pipeline development. (Euronext: POXEL, www.poxelpharma.com)

View Comments and Join the Discussion!